Efficacy and safety of leflunomide for Refractory novel coronavirus pneumonia (COVID-19): A non-Randomized Controlled Study

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2000033372

Enrollment

Unknown

Registered

2020-05-29

Start date

2020-03-12

Completion date

Unknown

Last updated

2020-06-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Novel Coronavirus Pneumonia (COVID-19)

Interventions

Experimental group:Standard treatment plus Oral leflunomide

Control group:Standard treatment

Eligibility

Sex/Gender

All

Age

43 Years to 70 Years

Inclusion criteria

Inclusion criteria: Hospitalized adult patients aged >=18 years with radiologically confirmed COVID-19 pneumonia who were reverse transcriptase-polymerase chain reaction (RT-PCR)-positive for SARS-CoV-2 for more than 28 days despite standard care. Eligible patients had pneumonia confirmed by chest imaging and had an oxygen saturation (SaO2) of 94% or higher on room air PaO2/FiO2 ratio >=300 mg Hg (ratio of the partial pressure of oxygen (PaO2) to the fraction of inspired oxygen (FiO2)).

Exclusion criteria

Exclusion criteria: Pregnancy, a history of liver disease, alanine aminotransferase level 5 times higher than the upper normal limit (50 U/L), and stage 4 chronic kidney disease.

Design outcomes

Primary

Measure	Time frame
SARS-CoV-2 clearance;	—

Countries

China

Contacts

Public ContactHu Zhao

Shandong University Qilu Hospital

sdhuzhao@vip.126.com+86 18560081616

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026